Pharsight

Purple Biotech patents expiration

1. Consensi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662315 PURPLE BIOTECH Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
May, 2029

(5 years from now)

US9408837 PURPLE BIOTECH Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
Feb, 2030

(6 years from now)

US10925835 PURPLE BIOTECH Celecoxib and amlodipine formulation and method of making the same
Jun, 2038

(14 years from now)

US10945960 PURPLE BIOTECH Celecoxib and amlodipine formulation and method of making the same
Jun, 2038

(14 years from now)

US10350171 PURPLE BIOTECH Celecoxib and amlodipine formulation and method of making the same
Jun, 2038

(14 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

How can I launch a generic of CONSENSI before it's drug patent expiration?
More Information on Dosage

CONSENSI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic